Market Overview:
The global GMP plasmid DNA market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for GMP plasmid DNA for various applications such as DNA vaccines, gene therapy, immunotherapy and others. Additionally, the increasing investment in R&D by biotechnology and pharmaceutical companies is also contributing to the growth of this market. However, stringent regulatory norms and high cost of production are some of the factors restraining the growth of this market. On basis on type, standard GMP plasmid DNA segment is expected to hold major share in global GMP plasmid DNA market during forecast period due its low cost and easy availability as compared to ultra-pure GMP plamdid DNAs segments.
Product Definition:
GMP plasmid DNA is a purified, double-stranded DNA molecule used for cloning and gene expression. GMP stands for "Good Manufacturing Practice," and the quality of this type of plasmid is assured by regulatory agencies such as the Food and Drug Administration (FDA) in the United States. GMP plasmids are commonly used in biotechnology research and manufacturing to produce recombinant proteins, vaccines, and other therapeutics.
Standard:
Standard is a new segment in GMP plasmid DNA market. It's usage as a raw material for the production of biopharmaceuticals and growth factor in pharmaceutical industry has increased the demand for standard over the past few years. The increase in demand can be attributed to factors such as growing expenditure on R&D, presence of strong manufacturing base, increasing number of contract research organizations (CROs), and rising focus on quality by default approach.
Ultra-Pure:
Ultra-Pure is a new term in the GMP plasmid DNA market and it basically means 99.99% pure. It is used to make sure that there are no other components present in the final product which may have originated from the original source of DNA preparation. Ultra-pure products are usually made using two methods, one is by Miltenyi Biotec’s proprietary technology and another one by Roche’s technology (QIAGEN).
Application Insights:
Plasmid DNA vaccines are expected to witness lucrative growth over the forecast period owing to their potential use in prevention of infectious diseases. Plasmids are small pieces of DNA that can be easily inserted into the host cells and express foreign proteins, which makes them a promising tool for vaccine development. The presence of several companies involved in research & development activities related to plasmid-based vaccines is anticipated to boost industry growth during the forecast period.
DNA Vaccines Application Report: Plasmid-based vaccines have been considered as an innovative approach for production of recombinant antigens with enhanced immunogenicity and fewer side effects compared with conventional methods such as viral vector systems or transgenic animals (recombinant retrovirus).
Regional Analysis:
North America dominated the global GMP plasmid DNA market in 2017. This is due to presence of a large number of biopharmaceutical manufacturing facilities and increasing R&D activities in this region. Moreover, high adoption rate for new technologies and stringent regulatory guidelines are also driving the regional market growth.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as rising healthcare expenditure, improving infrastructure & safety standards, increase in disposable income levels coupled with growing awareness about advanced treatment options among patients.
Growth Factors:
- Increasing demand for GMP plasmid DNA in the biotechnology and pharmaceutical industries for research and development purposes.
- Rising prevalence of genetic disorders and chronic diseases, which is expected to increase the demand for GMP plasmid DNA products for gene therapy applications.
- Growing investments by leading players in R&D activities to develop novel GMP plasmid DNA products.
- Technological advancements in the field of genomics that is expected to boost the demand for GMP plasmid DNA products over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
GMP Plasmid DNA Market Research Report
By Type
Standard, Ultra-Pure
By Application
DNA Vaccines, Gene Therapy, Immunotherapy, Others
By Companies
Cobra Bio, Waisman Biomanufacturing, Gedeon Richter, Eurogentec, VGXI, PlasmidFactory, Kaneka, Delphi Genetics, Nature Technology Corporation, LakePharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
137
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global GMP Plasmid DNA Market Report Segments:
The global GMP Plasmid DNA market is segmented on the basis of:
Types
Standard, Ultra-Pure
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
DNA Vaccines, Gene Therapy, Immunotherapy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cobra Bio
- Waisman Biomanufacturing
- Gedeon Richter
- Eurogentec
- VGXI
- PlasmidFactory
- Kaneka
- Delphi Genetics
- Nature Technology Corporation
- LakePharma
Highlights of The GMP Plasmid DNA Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Standard
- Ultra-Pure
- By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the GMP Plasmid DNA Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
GMP Plasmid DNA is a plasmid that contains genes from another organism, such as a virus. GMP Plasmid DNA can be used to create new viruses or to study the effects of viruses on cells.
Some of the key players operating in the gmp plasmid dna market are Cobra Bio, Waisman Biomanufacturing, Gedeon Richter, Eurogentec, VGXI, PlasmidFactory, Kaneka, Delphi Genetics, Nature Technology Corporation, LakePharma.
The gmp plasmid dna market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 GMP Plasmid DNA Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 GMP Plasmid DNA Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 GMP Plasmid DNA Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the GMP Plasmid DNA Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global GMP Plasmid DNA Market Size & Forecast, 2018-2028
4.5.1 GMP Plasmid DNA Market Size and Y-o-Y Growth
4.5.2 GMP Plasmid DNA Market Absolute $ Opportunity
Chapter 5 Global GMP Plasmid DNA Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 GMP Plasmid DNA Market Size Forecast by Type
5.2.1 Standard
5.2.2 Ultra-Pure
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global GMP Plasmid DNA Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 GMP Plasmid DNA Market Size Forecast by Applications
6.2.1 DNA Vaccines
6.2.2 Gene Therapy
6.2.3 Immunotherapy
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global GMP Plasmid DNA Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 GMP Plasmid DNA Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America GMP Plasmid DNA Analysis and Forecast
9.1 Introduction
9.2 North America GMP Plasmid DNA Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America GMP Plasmid DNA Market Size Forecast by Type
9.6.1 Standard
9.6.2 Ultra-Pure
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America GMP Plasmid DNA Market Size Forecast by Applications
9.10.1 DNA Vaccines
9.10.2 Gene Therapy
9.10.3 Immunotherapy
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe GMP Plasmid DNA Analysis and Forecast
10.1 Introduction
10.2 Europe GMP Plasmid DNA Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe GMP Plasmid DNA Market Size Forecast by Type
10.6.1 Standard
10.6.2 Ultra-Pure
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe GMP Plasmid DNA Market Size Forecast by Applications
10.10.1 DNA Vaccines
10.10.2 Gene Therapy
10.10.3 Immunotherapy
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific GMP Plasmid DNA Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific GMP Plasmid DNA Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific GMP Plasmid DNA Market Size Forecast by Type
11.6.1 Standard
11.6.2 Ultra-Pure
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific GMP Plasmid DNA Market Size Forecast by Applications
11.10.1 DNA Vaccines
11.10.2 Gene Therapy
11.10.3 Immunotherapy
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America GMP Plasmid DNA Analysis and Forecast
12.1 Introduction
12.2 Latin America GMP Plasmid DNA Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America GMP Plasmid DNA Market Size Forecast by Type
12.6.1 Standard
12.6.2 Ultra-Pure
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America GMP Plasmid DNA Market Size Forecast by Applications
12.10.1 DNA Vaccines
12.10.2 Gene Therapy
12.10.3 Immunotherapy
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) GMP Plasmid DNA Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) GMP Plasmid DNA Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) GMP Plasmid DNA Market Size Forecast by Type
13.6.1 Standard
13.6.2 Ultra-Pure
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) GMP Plasmid DNA Market Size Forecast by Applications
13.10.1 DNA Vaccines
13.10.2 Gene Therapy
13.10.3 Immunotherapy
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 GMP Plasmid DNA Market: Competitive Dashboard
14.2 Global GMP Plasmid DNA Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cobra Bio
14.3.2 Waisman Biomanufacturing
14.3.3 Gedeon Richter
14.3.4 Eurogentec
14.3.5 VGXI
14.3.6 PlasmidFactory
14.3.7 Kaneka
14.3.8 Delphi Genetics
14.3.9 Nature Technology Corporation
14.3.10 LakePharma
